Cancer research
Actuate Therapeutics, Inc. has initiated a Phase 1b trial to evaluate the safety and efficacy of a novel combination of its lead investigational drug, elraglusib, with Incyte's PD-1 inhibitor, retifanlimab, and modified FOLFIRINOX (mFOLFIRINOX) as frontline therapy in advanced pancreatic adenocarcinoma. The trial, led by Anwaar Saeed, MD,
Cancer research
A clinical trial, led by UNICANCER and in collaboration with the University of Warwick, aims to determine the effectiveness of a genetic test, Prosigna, in deciding whether to administer chemotherapy to premenopausal women with hormone-dependent breast cancer. The trial seeks to assess whether optimized hormonal treatment, including ovarian suppression, can
Cancer research
Caris Life Sciences has published a groundbreaking study in Nature Communications demonstrating the potential of AI-based image analysis to transform immunotherapy decisions and precision oncology. The study, which analyzed hematoxylin and eosin (H&E) images from over 35,000 patients, showed that Caris' AI model can improve the
Cancer research
A new study has found that a proportion of men with low-risk prostate cancer, specifically grade group 1 (GG1), have a higher-risk disease than previously suggested by biopsy. The study, published in JAMA Oncology, used data from over 117,000 men with localized GG1 prostate cancer and found that 60%
Cancer research
Researchers at Massachusetts General Hospital have made significant progress in the development of immunotherapies for IDH-mutant gliomas, a type of brain tumor that is notoriously challenging to treat. According to a new study published in the journal Cancers, these tumors have a unique immunosuppressive tumor microenvironment (TME) that hinders the
Cancer research
Recent research conducted at the University of Texas Medical Branch has shed light on the connection between prolonged use of immunosuppressive drugs and an increased risk of cancer in transplant patients. A team of investigators studied the risk of cancer associated with five commonly used immunosuppressive drugs: tacrolimus, cyclosporin, sirolimus,
Cancer research
Research from the Department of Medical Oncology at the Beijing Chest Hospital has shed new light on the prognostic value of dynamic C-reactive protein-to-lymphocyte ratio (CLR) in small cell lung cancer (SCLC) patients treated with chemoimmunotherapy. A retrospective study of 88 SCLC patients found a significant association between reduced CLR
Cancer research
Research conducted by the University of Ferrara in Italy has investigated the potential of rutin-containing cyclodextrin nanosystems as a dietary supplement for diabetics. The study, presented in the Journal of Drug Delivery Science and Technology, aimed to address the limitations of rutin's physico-chemical instability and poor solubility in
Cancer research
Research at Brigham and Women's Hospital has shed light on the influence of cross-specialty and intra-specialty factors on the adoption of minimally invasive surgery (MIS) for gastric cancers. The study, which spanned 2010-2019, utilized the National Cancer Database to analyze the impact of MIS use for colorectal cancers
Cancer research
Researchers at the Case Comprehensive Cancer Center are conducting a Phase 2 clinical trial to investigate the effectiveness of pulmonary rehabilitation for advanced lung cancer survivors. The study aims to recruit 85 participants from the USA and involve collaboration with the United States Department of Defense. The trial has two
Cancer research
Researchers from the University of Queensland have made significant breakthroughs in generating induced pluripotent stem cell (iPSC)-derived natural killer (NK) cells for cancer immunotherapy. According to a recent review published in Clinical & Translational Immunology, these cells hold promise as a scalable, consistent, and inexhaustible source of genetically modifiable
Cancer research
Researchers at Dalian University of Technology, in collaboration with other institutions, have made significant strides in cancer gene therapy, particularly in the treatment of glioblastoma (GBM). According to a recent study published in Phytomedicine, ginsenoside F2-modified liposomes delivering FTY720 have shown enhanced glioblastoma targeting and antitumor activity via ferroptosis. The
